Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Regeneron Pharmaceuticals, Inc. (REGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
576.20+3.84 (+0.67%)
At close: 4:00PM EDT
575.50 -0.70 (-0.12%)
After hours: 07:59PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Outside Bar (Bullish)

Outside Bar (Bullish)

Previous Close572.36
Open573.66
Bid570.44 x 800
Ask575.50 x 1100
Day's Range569.62 - 578.67
52 Week Range441.00 - 686.62
Volume627,309
Avg. Volume783,581
Market Cap61.217B
Beta (5Y Monthly)0.21
PE Ratio (TTM)10.40
EPS (TTM)55.38
Earnings DateNov 04, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est690.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
18% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for REGN

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Regeneron Pharmaceuticals, Inc.
    Analyst Report: Regeneron Pharmaceuticals, Inc.Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in atopic dermatitis, asthma, and nasal polyposis; Libtayo in cutaneous squamous cell carcinoma; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal antibodies with Sanofi in immunology and cancer, and bispecific antibodies and antibody cocktails with other collaborators and independently.
    Rating
    Fair Value
    Economic Moat
    27 days agoMorningstar
View more
Advertisement
Advertisement